Simplified management algorithm for patients who relapse after ASCT. The schema outlines a suggested approach to these patients, stratified according to prior or current exposure to brentuximab vedotin. Other options in terms of salvage chemotherapy-radiotherapy exist but have been omitted to reduce complexity. It is recognized that the decision to proceed to alloSCT is an individualized one that will be influenced by other clinical considerations, donor options, and patient views. Given that survival outcomes with T-cell–depleted alloSCT are no worse, and indeed may even be better than those with T-replete regimens,19 and additional concerns regarding GVHD risk after anti-PD-1 agents, use of a T-cell–depleted platform may be preferable after anti-PD-1 therapy. PD, progressive disease; PR, partial response; SD, stable disease.
